Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI read your blood tests and decide how soon you need a doctor?

NCT ID NCT07810491

Diagnosis Sponsor: Labplus Sp. z o.o. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing a certified AI software system that automatically interprets laboratory test results along with a structured medical history questionnaire. Adults at two university hospitals in Katowice, Poland, who are referred for lab testing complete an electronic questionnaire after their results are ready. The software then assigns each result an urgency category for medical contact, suggests a medical specialty, and recommends further tests. The study compares the software's urgency ratings with those of expert physicians to see how closely they agree.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based laboratory result interpretation software called LabTest Checker
What this could lead to
If it works, this software could help doctors spot urgent lab results faster and guide patients to the right specialist sooner.
What could go wrong
The software might misjudge how urgent a result is, especially in rare or complex cases. The study measures only how well the software matches expert doctors, not whether patients actually get better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 899 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Treated at one of the two participating clinical centers of the Medical University of Silesia * Age 18 years or older and under 80 years * Presence of symptoms justifying the initiation of a diagnostic work-up * Meets the criteria for ordering at least one of the 29 specialist laboratory panels included in the study * Able to complete an electronic questionnaire in Polish independently, using a smartphone or a personal computer * Holds a Polish national identification number (PESEL) * Written informed consent covering all three components of the study Exclusion Criteria: * Pregnancy * Age 80 years or older * Inability to provide informed consent, including cognitive impairment or a language barrier * Participation in another clinical study that could affect the results * Refusal of consent to any of the three components of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical laboratory techniques are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical laboratory techniques Diagnostic techniques and procedures TRIAGE

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Independent Public Clinical Hospital named after Andrzej Mielecki, Medical University of Silesia

    Katowice, Poland

    Contact Email: •••••@•••••

  • Prof. K. Gibinski University Clinical Center, Medical University of Silesia

    Katowice, Poland

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.